Introduction
FADD (Fas-associated protein with death domain) was first identified as a cytosolic adapter protein essential for mediating death receptor-induced apoptosis (1) (2) (3) . The FADD protein links to the cytoplasmic tail of active death receptors (DR), such as Fas, DR4, and DR5, where it binds procaspases-8 and -10, leading to the formation of the death-inducing signaling complex (DISC) at the cytosolic-side of the cell membrane. DISC formation initiates intracellular processing and activation of procaspases, which, in turn, initiates cleavage of the downstream targets, caspase-3, -6, and -7, and subsequently, apoptosis (4) (5) (6) . Besides its role in regulating death receptorinduced apoptosis, FADD is also implicated in a number of death receptor-induced nonapoptotic activities including, embryogenesis, cell-cycle progression, cell proliferation, and tumorigenesis (6) (7) (8) (9) (10) . Many of these non-apoptotic activities are determined by the level of phosphorylation of a specific C-terminal serine (Ser194) in a region distinct from the proapoptotic function related to the death domain (11) (12) .
Recent studies have led to a better understanding of the FADD gene and its location on chromosome 11q13.3 a hot spot for chromosomal amplification in a number of human cancers including breast, bladder, esophagus, lung, and head and neck carcinomas (13, 14) . Our recent studies provide evidence of overexpression of FADD mRNA and protein in human lung adenocarcinoma and its correlation to NF-țB activation. We have also demonstrated that highlevels of phosphorylated FADD (pFADD) predominantly localized to the nucleus in lung tumor cells, is a biomarker for aggressive disease as well as for poor clinical outcome (13) . The molecular basis for this correlation stems from the role of pFADD as a potent mediator of the 4 non-apoptotic transcription factor NF-țB (13, 15) , a known regulator of cell fate decisions such as, resistance to programmed cell death and lack of proliferation control (16) .
Phosphorylation of FADD at serine 194 has been shown to be mediated by casein kinase IĮ (CK1Į) (4) and FIST-HIPK3 (FADD-interacting serine-threonine kinase/homeodomaininteracting protein kinase 3) (17) but the exact regulation and role of pFADD in cancer are not well understood. In this research, we utilize a bioluminescent cell-based assay to characterize NSC 47147 as a potent inhibitor of FADD phosphorylation and to evaluate its potential as a therapeutic agent in cancer treatment.
penicillin. ATCC cell lines were tested routinely for mycoplasma and purity. All ATCC lines were expanded immediately upon receipt and multiple vials of low passage cells were maintained in liquid N 2 . No vial of cells was cultured for more than 1-2 months. A549-FKR and SW620-BGCR cells have been previously described (18) (19) . A549-FKR findings were validated using freshly obtained A549 cultures from the ATCC. Cultures were maintained in a humidified incubator at 37°C and 5% CO 2 and all cell culture experiments were done in serum-containing media. For in vitro and in vivo experiments, cells were removed from tissue culture dishes using 0.05% trypsin containing EDTA. Cell cultures were between 70% and 90% confluent at the time of harvest.
Western analysis
A549 and Jurkat cells were seeded at the appropriate density in six-well plates 24 hours before compound treatment. A549 cells were treated, washed twice with ice-cold PBS and lysed with extraction buffer [(1% NP40, 150 mM NaCl, 25 mM Tris (pH 8.0) supplemented with complete phosphatase and protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)]. Cell lysates were rocked at 4°C for 30 minutes. Particulate material was removed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The supernatants were collected and protein content estimated by a detergent compatible protein assay kit from Bio-Rad (Hercules, CA). Whole cell lysates containing equal amounts of protein (10-20 μg) were separated by 12% Bis-Tris polyacrylamide gels (Invitrogen, Carlsbad, CA), and transferred to PVDF membranes. The membranes were probed against specific primary antibodies followed by HRP-conjugated secondary antibodies and visualized using the Enhanced Chemiluminescence Plus Western Blotting System (GE Healthcare, Piscataway, NJ). 
Bioluminescent FADD-Kinase reporter assay
The bioluminescent FADD-kinase reporter assay was executed as previously described (18 
CK1Į inhibition assays
CK1Į enzymatic activity was evaluated using Lance Ultra CK2Į1/ȕ Kinase Assay (PerkinElmer, Shelton, CT) according to manufacturer's instructions. Recombinant CK1Į was purchased from ProQinase (Freiburg, Germany). Serial dilutions of NSC 47147 (1 to 100μM) and CKI7 (1 to 300 μM), were incubated with 25 nM CK1Į enzyme, 50nM ULight-Topo-IIĮ (Thr1342) Peptide and 1 μM ATP, final concentrations of inhibitors were in 2% DMSO. Kinase reactions were terminated after 30 minutes by the addition of EDTA. Experiments were performed in triplicate and the data was derived from a minimum of three independent experiments. Percent inhibition was calculated as % inhibition = (rate no inhibitor) -(rate with inhibitor)/(rate no inhibitor) x 100. A bioluminescent reporter cell line expressing a construct designed to monitor changes in CK1Į activity recently described by our lab (SW620 BGCR), was used to provide additional evidence that NSC 47147 inhibits FADD phosphorylation through inhibition of CK1Į. (19) . In brief, SW620-BGCR cells were plated in 12-well plates and treated with 250 μM CKI7 and 3 μM NSC 47147 for 3 hours. Bioluminescence was acquired on an IVIS 200 imaging platform (Caliper Life Science, Hopkinton, MA, USA) after adding 100 ȝg/ml d-luciferin (Xenogen, Alameda, CA, USA). Region of interest (ROI) values were calculated for each exposure and analyzed.
Bioluminescence measurements were performed in triplicate.
Cell viability assay
A549 cells were monitored for viability based on ATP levels 24-hours post NSC 47147 treatment. NSC 47147/Bortezomib, cisplatin sensitization experiments were preincubated with cisplatin for 24 hours followed by the addition of various doses of NSC 47147 or Bortezomib for 24 hours. Percent viability was measured using Cell Titer Glo Luminescent Cell Viability Assay (Promega, Madison, WI) and measured using the EnVision Xcite Multilabel Reader (PerkinElmer, Shelton, CT). Percent viability was calculated as A sample /A control x 100.
Phospho-IțB functional assay
Phospho-IțB levels were monitored in whole cell lysates using AlphaScreen SureFire p-IțB apoptosis by labeling and detecting DNA strand breaks using the TUNEL method.
Representative images were taken on an Olympus Bx-51 microscope with 20X magnification.
Statistical analysis
All data were expressed as the mean ± standard error of mean (SEM) from at least three independent experiments. Graph Pad Prism v.5 (GraphPad Prism version 5.01, GraphPad Software) nonlinear regression analysis, sigmoidal dose-response (variable slope) was used to generate the IC50 values. For tumor growth analysis, ANOVA was done on the proportional change of volume from baseline at each time point. If there was a significant difference, all pairwise comparisons were run adjusting for the multiple comparisons using Tukey's HSD (honest significant differences). Differences between groups were considered significant when the P value was 0.05.
Results

Identification of a FADD-kinase inhibitor, NSC 47147
Using the A549-FKR reporter assay to screen an NCI compound diversity set, we identified NSC 47147, a tripyrrole alkaloid compound that inhibits FADD phosphorylation (Fig. 1) . The compound increases FKR reporter activity in a concentration-dependent manner with an IC50 of 2.0 μM ( Fig. 2A) . Comparatively, the JNK inhibitor (SP600125), known to downregulate FIST-HIPK3 activity, and the CK1Į inhibitor (CKI7) also demonstrate a concentration-dependent increase in FKR bioluminescence with IC50 values of 22 μM and 143 μM, respectively ( It is important to note that in response to inhibition of FADD phosphorylation, corresponding levels of total FADD also show a decrease. We have previously demonstrated that inhibition of FADD phosphorylation results in its ubiquitin-dependent degradation. Using MG132, a proteosome inhibitor, have confirmed that a decrease in total FADD levels in response to FADD dephosphorylation (i.e., in the presence of a FADD kinase inhibitor) can be reversed by inhibiting proteosomal degradation (18) .
To delineate possible FADD-kinase targets of NSC 47147, we examined whether the compound inhibited phosphorylation of ȕ-catenin, a downstream target of CK1Į. Western analysis of A549
and Jurkat cells following 6-hour treatment with NSC 47147 demonstrate a decrease in phosphorylated ȕ-catenin (p-ȕ-catenin) protein (Fig. 2C) . The data shows a trend similar to the inhibition of p-ȕ-catenin expression following treatment with CKI7 (Fig 2B) . Three hour treatment of 250 μM CKI7 and 3 μM NSC 47147 of our recently described CK1Į reporter cell line (SW620-BGCR) resulted in 10-fold induction in bioluminescence activity indicative of CKIĮ inhibition (Fig 3A) . In this assay, CKI7 resulted in 7.5 fold increase in activity. To examine further the effect of NSC 47147 on CK1Į inhibition, we directly evaluated CK1Į enzymatic activity in response to the compound (Fig. 3B) . It is worth mentioning that maximal inhibition by NSC 47147 was not observed due to its limited aqueous solubility. However, the resulting IC50 for NSC 47147, 6 μM, supports the ability of NSC 47147 to inhibit CK1Į. Taken together; these results substantiate our finding that NSC 47147 inhibits phosphorylation of To examine the correlation of NSC 47147 activation of the FKR reporter and corresponding decrease in pFADD on cell viability, A549 lung carcinoma cells were treated with increasing concentrations of NSC 47147 and ATP levels were measured at 24-hours post-treatment. The increase in FKR reporter activity directly correlates with a decrease in percent cell viability.
Results demonstrate similar IC50s (2 μM) for both inhibition of pFADD, as indicated by increased reporter activity, and corresponding decrease in cell viability (Fig. 4) .
NSC 47147 inhibits NF-țB activation in A549 lung carcinoma cells
Our previous studies have demonstrated a close correlation between levels of pFADD and NF-țB activation (13) . Based on this evidence, we sought to examine the effect of NSC 47147 on the inhibition of both endogenous and TNFĮ-induced levels of phosphorylated IțBĮ, critical to transcriptional activity of NF-țB (16) . Treatment of A549 cells with 1, 3, and 6 μM NSC 47147 resulted in 31, 63, and 76 percent decrease in pIțBĮ activity, respectively, along with a corresponding decrease in protein expression of both pIțBĮ and total IțBĮ ( Fig. 5A and 5B).
A549 cells stimulated with TNFĮ following pretreatment with NSC 47147, demonstrate that the inhibitor also blocks TNFĮ induced IțBĮ phosphorylation (Fig. 5C) . Western blot analysis demonstrates that NSC 47147 inhibits TNFĮ-induced expression of pIțBĮ at 5-minutes poststimulation (Fig. 5D) as well as inhibiting the rapid IKK-dependent phosphorylation of IțBĮ before its degradation and the continued phosphorylation and turnover of newly synthesized IțBĮ 30-minutes after TNFĮ stimulation (Fig. 5D) (20) .
NSC 47147 as a chemosensitizing agent
We hypothesized that pFADD mediated NF-țB inhibition by NSC 47147 would sensitize tumor cells to chemotherapeutic agents and enhance tumor cell death. To test this hypothesis, A549 Bortezomib following which, ATP levels were measured. As shown in figure 6A , NSC 47147 treatment in combination with cisplatin leads to an increase in cell death (* P value 0.05) as compared to NSC 47147 treatment alone. As shown in figure 6B , treatment of A549 cells with bortezomib and cisplatin also resulted in a marked (* P value 0.05) decrease in cell viability.
These data suggest that the enhanced sensitivity to cisplatin in response to NSC 47147 or bortezomib treatment is due to inhibition of NF-țB.
To further confirm the cooperative effects of cisplatin and NSC 47147, A549 cells pretreated with cisplatin (10 μM) for 18 hours followed by 6-hour treatment with NSC 47147 (6 μM) were subjected to cell cycle analysis. Figure 6C shows 12.3% of cells in sub-G1 phase in response to NSC 47147/cisplatin combination treatment as compared to vehicle control (1.8%), NSC 47147 (1.6%) and cisplatin (5.2%) alone. Western analysis on similarly treated cells, resulted in an increase in caspase-3 cleavage with cisplatin, no effect with NSC 47147 alone, and a marked increase in cleaved caspase-3 levels (17 and 19 kDa bands) with combined NSC 47147 and cisplatin treatment (Fig. 6D) , thus supporting the capacity of NSC 47147 to augment cisplatininduced apoptosis. 
flanks of nude mice. When tumors reached a volume between 100-150 mm 3 , we monitored bioluminescence over time in mice treated with NSC 47147 or vehicle control. Bioluminescence imaging shows an increase in FKR reporter activity following treatment with NSC 47147, maximum reporter activity was reached within 6-hours followed by sustained, although lower, activity up to 36-hours (Fig. 7A) . Representative images of NSC 47147 treated mice are shown in Figure 7B .
The chemosensitizing effects of NSC 47147 on tumor progression were evaluated in A549-FKR mouse xenografts treated with NSC 47147 (3mg/kg) once daily for 8 days with or without cisplatin (2mg/kg) i.p. injections on days 1 and 7. Significant reduction (P 0.05) in tumor volume was observed at day 13 for the NSC 47147/cisplatin combination therapy as compared to control or either chemical agent alone (Fig. 7C) . Notably, mice treated with the combination therapy had no increase in tumor volume through the duration of the study, whereas mice treated with cisplatin or NSC 47147 alone resumed tumor growth at day 13 and day 7, respectively.
Based on these results, we evaluated the degree of apoptosis in the tumor xenografts following treatment with NSC 47147 alone or in combination with cisplatin. Immunohistological staining for apoptosis demonstrate areas of cell death within tumors of cisplatin treated mice, a small amount of apoptosis in tumors of NSC 47147 treated mice, and a pronounced increase in apoptosis throughout the tumors of mice receiving the combination of cisplatin and NSC 47147 (Fig. 7D ). 
Discussion
Although FADD was originally identified as a key mediator of apoptosis, it has recently been identified as a modulator of a number of death receptor dependent and independent nonapoptotic activities including, embryogenesis, cell-cycle progression, cell proliferation, and tumorigenesis (6, 8, 9) . Previous research from our lab has revealed phosphorylated FADD (pFADD) as a biomarker for poor clinical outcome in human lung adenocarcinoma. Our studies have demonstrated a strong correlation between high levels of phosphorylated FADD and elevated NF-țB activity, the anti-apoptotic actions of which lead to the formation of aggressive phenotypes, resistance to chemotherapeutic agents, and poor clinical outcome (13, 15, 21) . In this study, we provide evidence that abrogation of NF-țB signaling through small molecule inhibition of FADD phosphorylation is a novel and viable approach for cancer therapy.
Comprehensive studies recently conducted in A549 and Jurkat cell lines have provided insight into the mechanistic basis for FADD and its involvement in NF-țB activation and tumorigenesis (13, 22, 23) . Additionally, it was in Jurkat cells that CK1Į was identified as the kinase that phosphorylates FADD (4). Research from our lab has shown these lines to express high levels of phosphorylated FADD protein, thereby providing the impetus toward selecting these models for the identification and evaluation of a potential FADD-kinase inhibitor. Using A549 lung cancer cells expressing our recently described FADD-Kinase Reporter, FKR (18), we performed a high- phosphorylation and increase in cytotoxicity are a consequence of the same biological event. It has been proposed that the molecular basis for the correlation between pFADD levels and cell death stems from its role as a potent activator of NF-țB, an anti-apoptotic transcription factor (13) . Previous research has shown that overexpression of FADD stimulates NF-țB promoter activity (15, 28) and that FADD-deficient cells are more susceptible to viral infection due to defects in NF-țB activation (29) . Furthermore, FADD plays an integral role in the recently described TRADDosome complex, a central mediator of NF-țB signaling (30) . Although it was previously unappreciated, our published work has shown that increased levels of phosphorylated FADD result in elevated NF-țB activation (13) . The data presented in this paper provide further evidence that the phosphorylated form of FADD rather than FADD is a key component of the NF-țB activating complex.
The role of NF-țB in tumorigenesis has been well established and is based on its action as a regulator of cell fate decisions. It is often dysregulated in cancer cells leading to uncontrolled cell proliferation and resistance to therapeutic intervention (16) . These data show that A549 lung carcinoma cells treated with NSC 47147, yield a decrease in NF-țB activation as measured by the phosphorylation status of I-țBĮ. Phosphorylation of I-țBĮ by IKK (I kappa kinase) requires recruitment of the TRADDosome complex wherein IKK plays an essential role (30) . These results confirm previous reports that TNFĮ-induced NF-țB activation is dependent on levels of FADD expression (15, 31, 32) and provide further evidence of NSC 47147 as an inhibitor of FADD phosphorylation. 
Tumor cells with constitutively active NF-țB are known to be resistant to chemotherapeutic agents, a resistance that can be alleviated by inhibition of NF-țB signaling (16) . We hypothesized that pretreatment with NSC 47147 would chemosensitize A549 lung cancer cells toward an apoptotic stimulus leading to enhanced cell death. Results from our cell cycle analysis show a higher percentage of cells in the sub G1 population with a parallel increase in caspase-3 activity,thereby providing evidence that NSC 47147 sensitizes cells to cisplatin leading to decreased cell viability. We believe the mechanistic basis for the proposed synergy is that NSC 47147, by inhibiting FADD phosphorylation, abates TRADDosome mediated NF-țB activation.
In the absence of NF-țB signaling, tumor cells become sensitive to apoptotic stimuli (i.e. in response to cisplatin treatment). In this regard, our data shows that bortezomib induced NF-țB inhibition in combination with cisplatin also results in a decrease in cell viability. The ability of NSC 47147 to exhibit a similar outcome when used in combination with cisplatin provides additional mechanistic evidence that the cytotoxic effects of NSC 47147 are at least in part due to its inhibition of NF-țB.
Studies from our laboratory, as well as others, have also demonstrated a role of pFADD in G2/M progression (23, 33) . Therefore, we expected NSC 47147 to arrest cells at the G2/M phase of the cell cycle consistent with its proposed mechanism as an inhibitor of pFADD levels. As expected, the fraction of cells in G2/M following NSC 47147 treatment was 19.1% compared to 11.4% for control cells thereby providing additional support that NSC 47147 inhibits FADD phosphorylation leading to cell cycle arrest and cell death. Having demonstrated the in vitro effect of NSC 47147 alone and in combination with cisplatin, we next examined the compounds efficacy as a chemotherapeutic agent in a mouse tumor model. 
